Food and Drug Administration (FDA) approved protein biomarkers include cancer antigen 125 (CA125) in ovarian cancer, carcinoembryonic antigen (CEA) in colon cancer, and prostate-specific antigen (PSA) in prostate cancer [5]. This evidence concerns the gene CEACAM5 and ovarian cancer.